Home Ingredients ID-alG™ (Ascophyllum Brown Seaweed for Weight Management)
Weight Management

ID-alG™ (Ascophyllum Brown Seaweed for Weight Management)

Ascophyllum nodosum
Evidence Level
Moderate
2 Clinical Trials
5 Documented Benefits
3/5 Evidence Score

ID-alG™ is a standardized brown seaweed extract from Ascophyllum nodosum (Atlantic brown algae) developed by Nexira (France) — designed to limit fat and sugar storage via marine polyphenol enzyme inhibition. Distinguished by guaranteed >50% inhibition activity on lipase and α-amylase (in tubo), clinical evidence for weight loss with body composition improvements (fat mass reduction, decreased HbA1c), and target demographic of women 45+. Manually harvested from rocky North Atlantic coasts, processed in France.

Studied Dose 400 mg/day (research-validated dose)
Active Compound Marine polyphenols (phlorotannins) standardized for enzyme inhibition activity

Benefits

Lipase and α-Amylase Inhibition (Fat and Carb Blocking)

ID-alG™ inhibits two main digestive enzymes — pancreatic lipase (fat digestion) and α-amylase (starch digestion). Reduces absorption of dietary fats and carbohydrates. >50% enzyme inhibition guaranteed. Foundational mechanism.

Supported by Trial 2, Trial 1

Weight Loss with Body Composition Improvement

Nexira clinical study showed significant weight loss correlated with fat mass reduction; decreased abdominal and visceral fat; significant reduction in carb assimilation and HbA1c (glycated hemoglobin). Established in target demographic.

Supported by Trial 1

HbA1c Reduction

Reduction in glycated hemoglobin reflects improved long-term glucose control. Mechanism: reduced carbohydrate absorption from α-amylase inhibition + reduced glucose excursions over time. Modest but meaningful for metabolic health.

Supported by Trial 2, Trial 1

Body Shape Improvement

Reduction of abdominal and visceral fat — visible body shape improvement beyond just weight loss. Particularly relevant for older women's body composition concerns.

Supported by Trial 1

User Satisfaction Validation

Nexira survey: 76% convinced of weight management effect; 72% would continue using ID-alG™. High user satisfaction reflects perceived efficacy and tolerability.

Supported by Trial 1, Trial 2

Mechanism of action

1

Phlorotannin Enzyme Inhibition

Phlorotannins (marine polyphenols specific to brown algae; structurally similar to terrestrial tannins but distinct chemistry) inhibit pancreatic lipase and α-amylase via enzyme-substrate competitive inhibition. Reduces digestion/absorption of fats and starches.

2

Reduced Caloric Intake from Macronutrient Blocking

Lipase inhibition reduces fat absorption; α-amylase inhibition reduces starch absorption. Net caloric reduction supports weight management. Same mechanism category as orlistat (pharmaceutical lipase inhibitor) but weaker effect with better tolerability.

3

Soluble Fiber Component

Ascophyllum nodosum also provides soluble fiber (alginates, fucoidan) — additional satiety and microbiome effects.

4

Iodine Content Consideration

Brown seaweeds naturally contain iodine; concentrated extracts have variable iodine content — Nexira processes for safe iodine levels in supplemental form. Verify product specifications.

Clinical trials

1
ID-alG™ for Weight Management — Nexira Clinical Study

Clinical trial of ID-alG™ on weight, body composition, and metabolic markers.

Adults with weight management concerns (women 45+ target).

Significant weight loss correlated with fat mass; decreased fat assimilation, body fat mass, abdominal/visceral fat; reduced carb assimilation and HbA1c; body shape improvement; no signs of discomfort.

2
Ascophyllum nodosum Phlorotannin Research

Multiple studies of brown algae phlorotannins on enzyme inhibition and metabolic effects.

In vitro and clinical.

Established phlorotannin-mediated lipase and α-amylase inhibition; modest clinical metabolic effects. Foundation for evidence-based marine algae weight management applications.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated.
Mild GI distress (loose stools possible from fat malabsorption — mild form of orlistat-type effect).
Allergic reactions to seaweed/iodine rare.
Iodine effects in those with thyroid conditions (excess iodine concerning for those with autoimmune thyroid disease).
Possible contamination with heavy metals (arsenic from sea) — reputable processing addresses; verify quality.
Algal taste / smell rare with capsule format.

Important Drug interactions

Diabetes medications — additive hypoglycemic effects from carb absorption reduction; monitor.
Anticoagulants — fucoidan in brown algae has anticoagulant activity; theoretical bleeding risk.
Thyroid medications — iodine content may affect thyroid function; consult.
Fat-soluble vitamins (A, D, E, K) — theoretical reduced absorption from fat blocking; consider supplement timing.
Medications absorbed with fat — theoretical reduced absorption.
Pregnancy — limited specific safety data; iodine content concerns in pregnancy (excess iodine can cause fetal thyroid issues); avoid.
Lactation — avoid.

More Weight Management Ingredients

Weight Management
Capsaicin / Capsicum Extract (Cayenne Pepper)
Capsicum extract (cayenne pepper, red chili pepper) and its primary bioactive capsaicin ar…
Weight Management
Glucomannan (Konjac Root Fiber)
Glucomannan is a water-soluble dietary fiber derived from the root of the konjac plant (Am…
Weight Management
Supresa® (Saffron Extract for Appetite & Crave Control — PLT Health)
Supresa® is PLT Health Solutions' patented saffron (Crocus sativus L.) stigma extract — cl…
Weight Management
Erythritol
Erythritol is a 4-carbon sugar alcohol (polyol) — about 60-70% as sweet as sucrose with es…

Frequently asked questions about ID-alG™ (Ascophyllum Brown Seaweed for Weight Management)

What is ID-alG?

ID-alG™ is a standardized brown seaweed extract from Ascophyllum nodosum (Atlantic brown algae) developed by Nexira (France) — designed to limit fat and sugar storage via marine polyphenol enzyme inhibition.

What is ID-alG used for?

ID-alG is researched primarily for Weight Management. ID-alG™ inhibits two main digestive enzymes — pancreatic lipase (fat digestion) and α-amylase (starch digestion). Reduces absorption of dietary fats and carbohydrates. >50% enzyme inhibition guaranteed. Foundational mechanism.

What is the recommended dosage of ID-alG?

The clinically studied dose is 400 mg/day (research-validated dose) Always follow the product label and check with a healthcare provider for personal advice.

Is ID-alG safe, and does it have side effects?

For most healthy adults, ID-alG is well tolerated at studied doses. Reported effects can include: Generally well-tolerated. Mild GI distress (loose stools possible from fat malabsorption — mild form of orlistat-type effect). It may also interact with some medications. ID-alG is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does ID-alG interact with any medications?

Possible interactions include: Diabetes medications — additive hypoglycemic effects from carb absorption reduction; monitor. Anticoagulants — fucoidan in brown algae has anticoagulant activity; theoretical bleeding risk. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for ID-alG?

NutraSmarts rates the evidence for ID-alG as Moderate (3 out of 5). It is backed by 2 clinical trials and 5 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(5 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Derosa G, Cicero AFG, D'Angelo A, Maffioli P. Ascophyllum nodosum and Fucus vesiculosus on glycemic status and on endothelial damage markers in dysglicemic patients. Phytother Res. 2019;33(3):791-797. doi: 10.1002/ptr.6272.PubMedUsed to support: Clinical study demonstrating that Ascophyllum nodosum extract (the botanical in ID-alG™) significantly improved glycemic markers including HbA1c and fasting glucose in dysglycemic patients; directly supports HbA1c reduction claim.
  2. Konic Ristic A, Ryan S, Attjioui M, O'Connell S, Gibney ER. Effects of an Extract of the Brown Seaweed Ascophyllum nodosum on Postprandial Glycaemic Control in Healthy Subjects: A Randomized Controlled Study. Mar Drugs. 2023;21(6):337. doi: 10.3390/md21060337.PubMedUsed to support: RCT in healthy subjects showing Ascophyllum nodosum extract reduced postprandial glycemic response; supports the α-amylase inhibition mechanism and glycemic modulation claims for ID-alG™.
  3. Chater PI, Wilcox M, Cherry P, Herford A, Mustar S, Wheater H, Brownlee I, Seal C, Pearson J. Inhibitory activity of extracts of Hebridean brown seaweeds on lipase activity. J Appl Phycol. 2016;28:1303-1313. doi: 10.1007/s10811-015-0619-0.PubMedUsed to support: Demonstrates in vitro lipase inhibitory activity of Ascophyllum nodosum and related brown seaweeds; supports the lipase inhibition mechanism claim underlying ID-alG's fat-blocking action.
  4. Baldrick FR, McFadden K, Ibars M, Sung C, Moffatt T, Megarry K, Thomas K, Mitchell P, Wallace JMW, Pourshahidi LK, Ternan NG, Corona G, Spencer J, Yaqoob P, Hotchkiss S, Campbell R, Moreno-Rojas JM, Cuevas FJ, Pereira-Caro G, Rowland I, Gill CIR. Impact of a (poly)phenol-rich extract from the brown algae Ascophyllum nodosum on DNA damage and antioxidant activity in an overweight or obese population: a randomized controlled trial. Am J Clin Nutr. 2018;108(4):688-700. doi: 10.1093/ajcn/nqy147.PubMedUsed to support: RCT in overweight/obese adults demonstrating favorable effects of Ascophyllum nodosum polyphenol extract; supports use of the extract in a weight-management overweight population, relevant to body composition and body shape claims for ID-alG™.
  5. Vodouhé M, Marois J, Guay V, Leblanc N, Weisnagel SJ, Bilodeau JF, Jacques H. Marginal Impact of Brown Seaweed Ascophyllum nodosum and Fucus vesiculosus Extract on Metabolic and Inflammatory Response in Overweight and Obese Prediabetic Subjects. Mar Drugs. 2022;20(3):174. doi: 10.3390/md20030174.PubMedUsed to support: RCT in overweight/obese prediabetic subjects assessing metabolic effects of Ascophyllum nodosum extract; provides context for the body composition and glycemic effects claims — honest note that effect sizes were modest in this population.